VT-1953 / Vyome Therap - LARVOL DELTA

Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound (AACR 2026) - "Abstract is embargoed at this time."

Clinical • P2 data • Oncology

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months (Businesswire) - "FDA interaction on the Phase 3 protocol is planned in Q2 of 2026....The Company has required capital on hand to reach critical interim results from the Phase 3 efficacy study, expected in mid-2027."

FDA event • Orphan drug • P3 data • Inflammation • Oncology

Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects. (PubMed, Clin Drug Investig) - "VB-1953 topical gel appears to be safe for use in adults with facial acne vulgaris and may offer new advances as a topical antibiotic agent for the disease."

Clinical • Journal • P1 data • PK/PD data • Acne Vulgaris • Dermatology • Dermatopathology • Hematological Disorders